This places MilliporeSigma as the only provider with a patent for the fusion of chromatin-modulating peptides to CRISPR proteins. The ability to fuse chromatin, which often blocks DNA, with CRISPR-chrom technology improves efficiency of the gene-editing process, according to the company. The initial work on the technology was published in the CRISPR Journal in late February.
MilliporeSigma's full CRISPR patent portfolio includes CRISPR-related technologies covering foundational intellectual property and alternative genome-editing methods.
Copyright © 2020 scienceboard.net